Real‐World Clinical and Economic Outcomes in Selected Immune‐Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors

BACKGROUND: With increased use of immune checkpoint inhibitors (ICIs) among patients with cancer, there is substantial interest in understanding clinical and economic outcomes and management of immune‐related adverse events (irAEs). PATIENTS, MATERIALS, AND METHODS: A retrospective study was conduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Ying, Kim, Ruth, Yu, Ting, Gayle, Julie A., Wassel, Christina L., Dreyfus, Jill, Phatak, Hemant, George, Saby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Health Outcomes and Economics of Cancer Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571769/
https://www.ncbi.nlm.nih.gov/pubmed/34327774
http://dx.doi.org/10.1002/onco.13918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571769/
https://www.ncbi.nlm.nih.gov/pubmed/34327774
http://dx.doi.org/10.1002/onco.13918

Ejemplares similares